Interleukin-6 gene promoter-572 C allele may play a role in rate of disease progression in multiple sclerosis

Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Lotti Tajouri

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease affecting the central nervous system. Although the exact pathogenesis of MS is unknown, it is generally considered to be an autoimmune disease, with numerous genetic and environmental factors determining disease susceptibility and severity. One important mediator of immune responses and inflammation is interleukin-6 (IL-6). Previously, elevated levels of IL-6 in mononuclear cells in blood and in brain tissue from MS patients have been reported. Various polymorphisms in the promoter region of the IL6 gene have also been linked with IL-6 protein levels. In MS, several small studies have investigated whether two IL6 promoter polymorphisms (-597 G>A and -174 G>C) correlate with MS susceptibility, but with varying results. In the present study, we analyzed these polymorphisms, together with an additional polymorphism (-572 G>C) in 279 healthy controls and 509 patients with MS. We found no significant differences between MS patients and healthy controls for the different -597 or -174 IL6 promoter alleles or genotypes. There was a slight reduction in the percentage of individuals with MS who carried a C allele at position -572, although this was not significant after correction for multiple comparisons. Interestingly, however, the -572 C allele showed a significant correlation with the MS severity score, suggesting a possible role in disease progression.

Original languageEnglish
Pages (from-to)13667-13679
Number of pages13
JournalInternational Journal of Molecular Sciences
Volume13
Issue number10
DOIs
Publication statusPublished - 1 Oct 2012

    Fingerprint

Cite this